Upvote Story 7

Immunotherapy Effects on Sepsis

Immunotherapy Effects on Sepsis

A randomised controlled multicentre trial assessed for the first time the safety and pharmacokinetics of an antiprogrammed cell death-ligand 1 (anti–PD-L1) immune checkpoint inhibitor (BMS-936559; Bristol-Myers Squibb, Princeton, NJ) and its effect on immune biomarkers in participants with sepsis-associated immunosuppression.

Results show that BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinaemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days. The findings are published in the journal Critical Care Medicine. The trial included adult patients admitted to the ICU with sepsis or septic shock who had sepsis-associated immunosuppression as defined by an absolute lymphocyte count of less than or equal to 1,100 cells/μL.

CriticalCare.news
May 4, 2019

Leave Your Comment